PUBLISHER: Acute Market Reports | PRODUCT CODE: 1747437
PUBLISHER: Acute Market Reports | PRODUCT CODE: 1747437
Allergy Immunotherapy Market - Growth, Future Prospects and Competitive Analysis, 2025 - 2033
Allergy immunotherapy, also known as desensitization or hypo-sensitization, is a medical treatment designed to reduce the severity of allergic reactions over time by gradually exposing a patient to increasing doses of the specific allergen responsible for their symptoms. This process helps the immune system build tolerance to the allergen, thereby reducing the frequency and intensity of allergic responses. Immunotherapy is typically administered through subcutaneous injections (SCIT) or sublingual tablets or drops (SLIT), and it targets conditions such as allergic rhinitis, asthma, allergic conjunctivitis, and insect venom allergies. The global allergy immunotherapy market is expected to grow at a compound annual growth rate (CAGR) of 9.7% from 2025 to 2033. This growth is primarily driven by the rising global prevalence of allergic disorders, growing awareness of long-term treatment options beyond symptomatic relief, and advancements in allergen formulation technologies. With environmental pollution, urbanization, and lifestyle changes contributing to increased sensitivity to airborne allergens and food allergens, more patients are seeking lasting treatments. Immunotherapy offers a disease-modifying approach, distinguishing it from conventional antihistamines or corticosteroids, which only manage symptoms temporarily. Subcutaneous immunotherapy continues to dominate in clinical settings, but sublingual options are gaining popularity due to convenience, better patient compliance, and suitability for home administration.
Rising Prevalence of Allergic Disorders and Shift Toward Long-Term Disease-Modifying Therapies
One of the primary drivers contributing to the growth of the allergy immunotherapy market is the rising global prevalence of allergic conditions such as allergic rhinitis, asthma, and atopic dermatitis, which has resulted in a higher patient burden and greater demand for sustainable treatment options. Urbanization, environmental pollution, dietary changes, and increased exposure to indoor allergens have significantly heightened the incidence of allergy-related diseases across both developed and developing nations. In regions with dense populations and poor air quality, such as urban centers in Asia and Europe, respiratory allergies have become more common among both children and adults. This surge in allergic conditions has highlighted the limitations of symptomatic treatments like antihistamines and corticosteroids, which offer temporary relief but do not address the underlying immune response. Allergy immunotherapy, by contrast, works through gradual desensitization to specific allergens, offering a long-term solution by modifying the natural course of the disease. Clinical studies have shown that immunotherapy can reduce the progression of allergic rhinitis into asthma and can lead to long-term remission even after discontinuation of treatment. As a result, healthcare providers and allergists are increasingly recommending immunotherapy, particularly sublingual options, to patients with moderate to severe symptoms or those who do not respond well to traditional pharmacotherapy.
Expansion of Sublingual Immunotherapy (SLIT) and Home-Based Treatment Models
A significant opportunity in the allergy immunotherapy market lies in the expanding adoption of sublingual immunotherapy (SLIT) as a convenient, patient-friendly alternative to traditional subcutaneous injections (SCIT), particularly within home-based treatment frameworks. SLIT involves placing allergen-based tablets or drops under the tongue, allowing the immune system to gradually develop tolerance to allergens without the need for frequent clinic visits. This route has gained substantial traction in recent years, especially in Europe and North America, where patients increasingly seek non-invasive, flexible therapies that can be self-administered without compromising efficacy. The safety profile of SLIT, with lower risk of severe systemic reactions compared to SCIT, further supports its suitability for unsupervised use in home environments.
High Treatment Duration and Low Patient Adherence Rates
Despite its long-term clinical benefits, a significant restraint limiting the widespread adoption of allergy immunotherapy is the high treatment duration and associated challenges with patient adherence. Both subcutaneous and sublingual immunotherapy typically require an initial build-up phase followed by a maintenance phase that can last three to five years, making it one of the most prolonged therapeutic regimens among chronic disease treatments. This extended commitment poses a substantial burden on patients, particularly those with demanding lifestyles, financial constraints, or limited access to specialized healthcare providers. In SCIT, frequent clinic visits for injections-often weekly during the initiation phase-can disrupt work and school schedules, leading many patients to abandon treatment prematurely. Even SLIT, despite being more convenient and home-based, still requires daily administration over several years, which can lead to reduced motivation, missed doses, and eventual dropout. Surveys have shown that a significant percentage of patients fail to complete the full course of immunotherapy, thereby diminishing its long-term effectiveness and raising concerns among clinicians regarding cost-efficiency and treatment planning.
Allergen Standardization and Limited Availability of Personalized Formulations
A critical challenge in the allergy immunotherapy market is the lack of global standardization in allergen extracts and the limited availability of personalized formulations tailored to patient-specific allergen profiles. Unlike conventional pharmaceuticals, allergen extracts used in immunotherapy are biologically derived and exhibit significant variability depending on source material, preparation methods, and regional exposure patterns. This heterogeneity complicates dosing accuracy, efficacy comparison across markets, and regulatory approvals, particularly in regions where national pharmacopoeias differ or allergen panels are not harmonized. Patients in different geographic regions are often exposed to unique combinations of pollens, dust mites, molds, and animal dander, requiring highly specific treatment formulations that are not always readily available.
Market Segmentation by Allergy
In 2024, allergic rhinitis accounted for the highest revenue share in the global allergy immunotherapy market, driven by its widespread prevalence across all age groups and high seasonal recurrence rates due to pollen exposure, indoor allergens, and air pollution. The condition, which includes hay fever and dust mite allergies, affects a substantial portion of the global population, particularly in urban environments with high pollution levels, thereby creating sustained demand for long-term treatment solutions like immunotherapy. Immunotherapy for allergic rhinitis is well established, with both SCIT and SLIT options readily available, and is often covered under insurance in developed healthcare systems, further supporting revenue dominance. However, food allergy is expected to register the highest CAGR during the forecast period from 2025 to 2033, owing to rising global incidence, heightened awareness of life-threatening anaphylactic reactions, and recent advancements in targeted oral and epicutaneous immunotherapies aimed at desensitizing individuals to specific food proteins such as peanuts, milk, and eggs. The food allergy segment is also benefiting from a surge in pediatric diagnoses and growing research investments in immunotherapeutic vaccine development. Skin allergies, including atopic dermatitis and contact dermatitis, represent a growing segment due to environmental and lifestyle factors, although immunotherapy for skin allergies remains limited and largely supportive in nature. Insect-bite allergies-particularly from bees, wasps, and fire ants-have shown consistent but smaller revenue contributions, primarily focused in North America and parts of Europe where venom immunotherapy is routinely administered in controlled settings.
Market Segmentation by Treatment
In 2024, subcutaneous immunotherapy (SCIT) held the highest revenue share in the global allergy immunotherapy market, supported by its long-standing clinical use, proven efficacy across a wide range of allergens, and strong adoption within specialist allergy clinics, particularly in North America and Europe. SCIT involves periodic administration of allergen extracts via injections over a build-up and maintenance phase, with established safety profiles and standardized protocols that make it the preferred method for treating moderate to severe allergic rhinitis, asthma, and insect venom allergies. The ability to customize dosages and combine multiple allergens has further cemented SCIT's role in complex allergic profiles, especially in poly-sensitized patients. However, sublingual immunotherapy (SLIT) is expected to register the highest CAGR between 2025 and 2033 due to its non-invasive nature, ease of at-home administration, and increasing availability of regulatory-approved tablet formulations for allergens such as grass pollen, ragweed, and dust mites. SLIT is particularly appealing for pediatric and needle-averse populations and is gaining momentum in regions with growing patient demand for flexible, self-managed treatment options. The COVID-19 pandemic further accelerated the shift toward home-based therapies, prompting healthcare providers and patients alike to favor SLIT for its lower risk of systemic reactions and reduced need for in-clinic supervision. Pharmaceutical companies are increasingly investing in expanding the SLIT pipeline beyond respiratory allergens into food allergies and exploring novel delivery technologies to improve patient adherence and efficacy. While SCIT will continue to lead in complex case management and established healthcare settings, SLIT's rapid growth trajectory is being fueled by rising consumer preference for convenience, evolving regulatory approvals, and ongoing technological innovation that supports broader allergen coverage and improved treatment adherence.
Regional Insights
In 2024, Europe held the highest revenue share in the global allergy immunotherapy market, supported by a well-established regulatory framework, widespread clinical acceptance of immunotherapy, and high awareness among both patients and healthcare providers regarding long-term allergic disease management. Countries such as Germany, France, the United Kingdom, and Spain contributed significantly to regional revenues, where allergen-specific immunotherapy has been part of standard clinical practice for decades, particularly in managing allergic rhinitis and pollen-induced asthma. Reimbursement coverage for subcutaneous and sublingual treatments, including pre-seasonal and perennial options, further strengthened patient access and adherence. The region also benefited from strong participation in clinical trials and academic collaborations, with several key manufacturers headquartered in Europe investing in expanding treatment indications and delivery platforms. North America followed closely in revenue share, driven by the growing incidence of food allergies, favorable FDA approvals of SLIT tablets and oral immunotherapy products, and increasing adoption of allergen immunotherapy among pediatric populations. The U.S. market showed strong uptake of peanut desensitization therapies and venom immunotherapy, alongside expanding use of SLIT for dust mite and grass allergies.
Competitive Trends and Key Strategies
In 2024, the global allergy immunotherapy market was led by a mix of established pharmaceutical companies and innovative biotech firms, each adopting differentiated strategies to strengthen their market position through portfolio expansion, regulatory engagement, and R&D innovation. ALK-Abello A/S maintained its leadership by offering a broad portfolio of sublingual tablet therapies for respiratory allergies, investing heavily in real-world data collection, and expanding geographic reach in Asia and Latin America through strategic partnerships and licensing agreements. Stallergenes Greer emphasized its dual strength in both SCIT and SLIT formats, focusing on tailored multi-allergen formulations and next-generation recombinant allergen platforms to enhance personalization and efficacy. Allergy Therapeutics pursued growth via advanced adjuvanted vaccines and clinical-stage therapies for seasonal and perennial allergies, supported by ongoing trials in Europe and North America. Merck KGaA concentrated on European market penetration through SLIT products and sought to deepen its involvement in immunology-based innovation. HAL Allergy Group leveraged its manufacturing and R&D capabilities to supply immunotherapy products across Germany, the Netherlands, and Austria while expanding into emerging European regions. DBV Technologies focused on novel non-invasive platforms for food allergy treatment, particularly through epicutaneous delivery systems targeting pediatric populations. Aimmune Therapeutics, backed by a strong commercialization network, advanced its FDA-approved peanut immunotherapy while exploring pipeline development in other food allergens. Anergis and Biomay AG concentrated on recombinant allergen-based therapies and peptide immunotherapy approaches, seeking faster onset and shorter treatment durations. Carcassia, meanwhile, invested in novel dosing strategies and multi-indication immunotherapy candidates to address unmet needs in poly-sensitized patients. From 2025 to 2033, companies are expected to continue prioritizing regulatory approvals in new geographies, particularly in Asia and Latin America, while broadening their pipelines to include food allergies, skin allergies, and drug desensitization therapies. Strategic alliances with digital health platforms, AI-based diagnostic firms, and specialty care providers are anticipated to support patient monitoring, treatment adherence, and personalized care delivery.
Historical & Forecast Period
This study report represents an analysis of each segment from 2023 to 2033 considering 2024 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2025 to 2033.
The current report comprises quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends & technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. The key data points that enable the estimation of Allergy Immunotherapy market are as follows:
Research and development budgets of manufacturers and government spending
Revenues of key companies in the market segment
Number of end users & consumption volume, price, and value.
Geographical revenues generated by countries considered in the report
Micro and macro environment factors that are currently influencing the Allergy Immunotherapy market and their expected impact during the forecast period.
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top-down and bottom-up approach for validation of market estimation assures logical, methodical, and mathematical consistency of the quantitative data.
Market Segmentation
- Allergy
- Food Allergy
- Allergic Rhinitis
- Skin Allergy
- Insect-bite Allergy
- Other Allergies (Drug Allergy, Eye Allergy, Latex Allergy, etc.)
- Treatment
- Subcutaneous Immunotherapy (SCIT)
- Sublingual Immunotherapy (SLIT)
- Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Region Segment (2023-2033; US$ Million)
- North America
- U.S.
- Canada
- Rest of North America
- UK and European Union
- UK
- Germany
- Spain
- Italy
- France
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East and Africa
- GCC
- Africa
- Rest of Middle East and Africa
Key questions answered in this report
- What are the key micro and macro environmental factors that are impacting the growth of Allergy Immunotherapy market?
- What are the key investment pockets concerning product segments and geographies currently and during the forecast period?
- Estimated forecast and market projections up to 2033.
- Which segment accounts for the fastest CAGR during the forecast period?
- Which market segment holds a larger market share and why?
- Are low and middle-income economies investing in the Allergy Immunotherapy market?
- Which is the largest regional market for Allergy Immunotherapy market?
- What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
- Which are the key trends driving Allergy Immunotherapy market growth?
- Who are the key competitors and what are their key strategies to enhance their market presence in the Allergy Immunotherapy market worldwide?
Table of Contents
1. Preface
- 1.1. Report Description
- 1.1.1. Purpose of the Report
- 1.1.2. Target Audience
- 1.1.3. Key Offerings
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.3.1. Phase I - Secondary Research
- 1.3.2. Phase II - Primary Research
- 1.3.3. Phase III - Expert Panel Review
- 1.3.4. Assumptions
- 1.3.5. Approach Adopted
2. Executive Summary
- 2.1. Market Snapshot: Global Allergy Immunotherapy Market
- 2.2. Global Allergy Immunotherapy Market, By Allergy, 2024 (US$ Million)
- 2.3. Global Allergy Immunotherapy Market, By Treatment, 2024 (US$ Million)
- 2.4. Global Allergy Immunotherapy Market, By Distribution Channel, 2024 (US$ Million)
- 2.5. Global Allergy Immunotherapy Market, By Geography, 2024 (US$ Million)
- 2.6. Attractive Investment Proposition by Geography, 2024
3. Allergy Immunotherapy Market: Competitive Analysis
- 3.1. Market Positioning of Key Allergy Immunotherapy Market Vendors
- 3.2. Strategies Adopted by Allergy Immunotherapy Market Vendors
4. Allergy Immunotherapy Market: Macro Analysis & Market Dynamics
- 4.1. Introduction
- 4.2. Global Allergy Immunotherapy Market Value, 2023 - 2033, (US$ Million)
- 4.3. Market Dynamics
- 4.3.1. Market Drivers
- 4.3.2. Market Restraints
- 4.3.3. Key Challenges
- 4.3.4. Key Opportunities
- 4.4. Impact Analysis of Drivers and Restraints
- 4.5. Porter's Five Force Model
- 4.5.1. Supplier Power
- 4.5.2. Buyer Power
- 4.5.3. Threat Of Substitutes
- 4.5.4. Threat Of New Entrants
- 4.5.5. Competitive Rivalry
- 4.6. PESTEL Analysis
- 4.6.1. Political Landscape
- 4.6.2. Economic Landscape
- 4.6.3. Technology Landscape
- 4.6.4. Legal Landscape
- 4.6.5. Social Landscape
5. Allergy Immunotherapy Market: By Allergy, 2023-2033, USD (Million)
- 5.1. Market Overview
- 5.2. Growth & Revenue Analysis: 2024 Versus 2033
- 5.3. Market Segmentation
- 5.3.1. Food Allergy
- 5.3.2. Allergic Rhinitis
- 5.3.3. Skin Allergy
- 5.3.4. Insect-bite Allergy
- 5.3.5. Other Allergies (Drug Allergy, Eye Allergy, Latex Allergy, etc.)
6. Allergy Immunotherapy Market: By Treatment, 2023-2033, USD (Million)
- 6.1. Market Overview
- 6.2. Growth & Revenue Analysis: 2024 Versus 2033
- 6.3. Market Segmentation
- 6.3.1. Subcutaneous Immunotherapy (SCIT)
- 6.3.2. Sublingual Immunotherapy (SLIT)
7. Allergy Immunotherapy Market: By Distribution Channel, 2023-2033, USD (Million)
- 7.1. Market Overview
- 7.2. Growth & Revenue Analysis: 2024 Versus 2033
- 7.3. Market Segmentation
- 7.3.1. Hospital Pharmacy
- 7.3.2. Retail Pharmacy
- 7.3.3. Online Pharmacy
8. North America Allergy Immunotherapy Market, 2023-2033, USD (Million)
- 8.1. Market Overview
- 8.2. Allergy Immunotherapy Market: By Allergy, 2023-2033, USD (Million)
- 8.3. Allergy Immunotherapy Market: By Treatment, 2023-2033, USD (Million)
- 8.4. Allergy Immunotherapy Market: By Distribution Channel, 2023-2033, USD (Million)
- 8.5. Allergy Immunotherapy Market: By Region, 2023-2033, USD (Million)
- 8.5.1. North America
- 8.5.1.1. U.S.
- 8.5.1.1.1. Allergy Immunotherapy Market: By Allergy, 2023-2033, USD (Million)
- 8.5.1.1.2. Allergy Immunotherapy Market: By Treatment, 2023-2033, USD (Million)
- 8.5.1.1.3. Allergy Immunotherapy Market: By Distribution Channel, 2023-2033, USD (Million)
- 8.5.1.2. Canada
- 8.5.1.2.1. Allergy Immunotherapy Market: By Allergy, 2023-2033, USD (Million)
- 8.5.1.2.2. Allergy Immunotherapy Market: By Treatment, 2023-2033, USD (Million)
- 8.5.1.2.3. Allergy Immunotherapy Market: By Distribution Channel, 2023-2033, USD (Million)
- 8.5.1.3. Rest of North America
- 8.5.1.3.1. Allergy Immunotherapy Market: By Allergy, 2023-2033, USD (Million)
- 8.5.1.3.2. Allergy Immunotherapy Market: By Treatment, 2023-2033, USD (Million)
- 8.5.1.3.3. Allergy Immunotherapy Market: By Distribution Channel, 2023-2033, USD (Million)
- 8.5.1.1. U.S.
- 8.5.1. North America
9. UK and European Union Allergy Immunotherapy Market, 2023-2033, USD (Million)
- 9.1. Market Overview
- 9.2. Allergy Immunotherapy Market: By Allergy, 2023-2033, USD (Million)
- 9.3. Allergy Immunotherapy Market: By Treatment, 2023-2033, USD (Million)
- 9.4. Allergy Immunotherapy Market: By Distribution Channel, 2023-2033, USD (Million)
- 9.5. Allergy Immunotherapy Market: By Region, 2023-2033, USD (Million)
- 9.5.1. UK and European Union
- 9.5.1.1. UK
- 9.5.1.1.1. Allergy Immunotherapy Market: By Allergy, 2023-2033, USD (Million)
- 9.5.1.1.2. Allergy Immunotherapy Market: By Treatment, 2023-2033, USD (Million)
- 9.5.1.1.3. Allergy Immunotherapy Market: By Distribution Channel, 2023-2033, USD (Million)
- 9.5.1.2. Germany
- 9.5.1.2.1. Allergy Immunotherapy Market: By Allergy, 2023-2033, USD (Million)
- 9.5.1.2.2. Allergy Immunotherapy Market: By Treatment, 2023-2033, USD (Million)
- 9.5.1.2.3. Allergy Immunotherapy Market: By Distribution Channel, 2023-2033, USD (Million)
- 9.5.1.3. Spain
- 9.5.1.3.1. Allergy Immunotherapy Market: By Allergy, 2023-2033, USD (Million)
- 9.5.1.3.2. Allergy Immunotherapy Market: By Treatment, 2023-2033, USD (Million)
- 9.5.1.3.3. Allergy Immunotherapy Market: By Distribution Channel, 2023-2033, USD (Million)
- 9.5.1.4. Italy
- 9.5.1.4.1. Allergy Immunotherapy Market: By Allergy, 2023-2033, USD (Million)
- 9.5.1.4.2. Allergy Immunotherapy Market: By Treatment, 2023-2033, USD (Million)
- 9.5.1.4.3. Allergy Immunotherapy Market: By Distribution Channel, 2023-2033, USD (Million)
- 9.5.1.5. France
- 9.5.1.5.1. Allergy Immunotherapy Market: By Allergy, 2023-2033, USD (Million)
- 9.5.1.5.2. Allergy Immunotherapy Market: By Treatment, 2023-2033, USD (Million)
- 9.5.1.5.3. Allergy Immunotherapy Market: By Distribution Channel, 2023-2033, USD (Million)
- 9.5.1.6. Rest of Europe
- 9.5.1.6.1. Allergy Immunotherapy Market: By Allergy, 2023-2033, USD (Million)
- 9.5.1.6.2. Allergy Immunotherapy Market: By Treatment, 2023-2033, USD (Million)
- 9.5.1.6.3. Allergy Immunotherapy Market: By Distribution Channel, 2023-2033, USD (Million)
- 9.5.1.1. UK
- 9.5.1. UK and European Union
10. Asia Pacific Allergy Immunotherapy Market, 2023-2033, USD (Million)
- 10.1. Market Overview
- 10.2. Allergy Immunotherapy Market: By Allergy, 2023-2033, USD (Million)
- 10.3. Allergy Immunotherapy Market: By Treatment, 2023-2033, USD (Million)
- 10.4. Allergy Immunotherapy Market: By Distribution Channel, 2023-2033, USD (Million)
- 10.5. Allergy Immunotherapy Market: By Region, 2023-2033, USD (Million)
- 10.5.1. Asia Pacific
- 10.5.1.1. China
- 10.5.1.1.1. Allergy Immunotherapy Market: By Allergy, 2023-2033, USD (Million)
- 10.5.1.1.2. Allergy Immunotherapy Market: By Treatment, 2023-2033, USD (Million)
- 10.5.1.1.3. Allergy Immunotherapy Market: By Distribution Channel, 2023-2033, USD (Million)
- 10.5.1.2. Japan
- 10.5.1.2.1. Allergy Immunotherapy Market: By Allergy, 2023-2033, USD (Million)
- 10.5.1.2.2. Allergy Immunotherapy Market: By Treatment, 2023-2033, USD (Million)
- 10.5.1.2.3. Allergy Immunotherapy Market: By Distribution Channel, 2023-2033, USD (Million)
- 10.5.1.3. India
- 10.5.1.3.1. Allergy Immunotherapy Market: By Allergy, 2023-2033, USD (Million)
- 10.5.1.3.2. Allergy Immunotherapy Market: By Treatment, 2023-2033, USD (Million)
- 10.5.1.3.3. Allergy Immunotherapy Market: By Distribution Channel, 2023-2033, USD (Million)
- 10.5.1.4. Australia
- 10.5.1.4.1. Allergy Immunotherapy Market: By Allergy, 2023-2033, USD (Million)
- 10.5.1.4.2. Allergy Immunotherapy Market: By Treatment, 2023-2033, USD (Million)
- 10.5.1.4.3. Allergy Immunotherapy Market: By Distribution Channel, 2023-2033, USD (Million)
- 10.5.1.5. South Korea
- 10.5.1.5.1. Allergy Immunotherapy Market: By Allergy, 2023-2033, USD (Million)
- 10.5.1.5.2. Allergy Immunotherapy Market: By Treatment, 2023-2033, USD (Million)
- 10.5.1.5.3. Allergy Immunotherapy Market: By Distribution Channel, 2023-2033, USD (Million)
- 10.5.1.6. Rest of Asia Pacific
- 10.5.1.6.1. Allergy Immunotherapy Market: By Allergy, 2023-2033, USD (Million)
- 10.5.1.6.2. Allergy Immunotherapy Market: By Treatment, 2023-2033, USD (Million)
- 10.5.1.6.3. Allergy Immunotherapy Market: By Distribution Channel, 2023-2033, USD (Million)
- 10.5.1.1. China
- 10.5.1. Asia Pacific
11. Latin America Allergy Immunotherapy Market, 2023-2033, USD (Million)
- 11.1. Market Overview
- 11.2. Allergy Immunotherapy Market: By Allergy, 2023-2033, USD (Million)
- 11.3. Allergy Immunotherapy Market: By Treatment, 2023-2033, USD (Million)
- 11.4. Allergy Immunotherapy Market: By Distribution Channel, 2023-2033, USD (Million)
- 11.5. Allergy Immunotherapy Market: By Region, 2023-2033, USD (Million)
- 11.5.1. Latin America
- 11.5.1.1. Brazil
- 11.5.1.1.1. Allergy Immunotherapy Market: By Allergy, 2023-2033, USD (Million)
- 11.5.1.1.2. Allergy Immunotherapy Market: By Treatment, 2023-2033, USD (Million)
- 11.5.1.1.3. Allergy Immunotherapy Market: By Distribution Channel, 2023-2033, USD (Million)
- 11.5.1.2. Mexico
- 11.5.1.2.1. Allergy Immunotherapy Market: By Allergy, 2023-2033, USD (Million)
- 11.5.1.2.2. Allergy Immunotherapy Market: By Treatment, 2023-2033, USD (Million)
- 11.5.1.2.3. Allergy Immunotherapy Market: By Distribution Channel, 2023-2033, USD (Million)
- 11.5.1.3. Rest of Latin America
- 11.5.1.3.1. Allergy Immunotherapy Market: By Allergy, 2023-2033, USD (Million)
- 11.5.1.3.2. Allergy Immunotherapy Market: By Treatment, 2023-2033, USD (Million)
- 11.5.1.3.3. Allergy Immunotherapy Market: By Distribution Channel, 2023-2033, USD (Million)
- 11.5.1.1. Brazil
- 11.5.1. Latin America
12. Middle East and Africa Allergy Immunotherapy Market, 2023-2033, USD (Million)
- 12.1. Market Overview
- 12.2. Allergy Immunotherapy Market: By Allergy, 2023-2033, USD (Million)
- 12.3. Allergy Immunotherapy Market: By Treatment, 2023-2033, USD (Million)
- 12.4. Allergy Immunotherapy Market: By Distribution Channel, 2023-2033, USD (Million)
- 12.5. Allergy Immunotherapy Market: By Region, 2023-2033, USD (Million)
- 12.5.1. Middle East and Africa
- 12.5.1.1. GCC
- 12.5.1.1.1. Allergy Immunotherapy Market: By Allergy, 2023-2033, USD (Million)
- 12.5.1.1.2. Allergy Immunotherapy Market: By Treatment, 2023-2033, USD (Million)
- 12.5.1.1.3. Allergy Immunotherapy Market: By Distribution Channel, 2023-2033, USD (Million)
- 12.5.1.2. Africa
- 12.5.1.2.1. Allergy Immunotherapy Market: By Allergy, 2023-2033, USD (Million)
- 12.5.1.2.2. Allergy Immunotherapy Market: By Treatment, 2023-2033, USD (Million)
- 12.5.1.2.3. Allergy Immunotherapy Market: By Distribution Channel, 2023-2033, USD (Million)
- 12.5.1.3. Rest of Middle East and Africa
- 12.5.1.3.1. Allergy Immunotherapy Market: By Allergy, 2023-2033, USD (Million)
- 12.5.1.3.2. Allergy Immunotherapy Market: By Treatment, 2023-2033, USD (Million)
- 12.5.1.3.3. Allergy Immunotherapy Market: By Distribution Channel, 2023-2033, USD (Million)
- 12.5.1.1. GCC
- 12.5.1. Middle East and Africa
13. Company Profile
- 13.1. ALK-Abello A/S
(Company Overview, Financial Performance, Product Portfolio, Strategic Initiatives)
- 13.2. Allergy Therapeutics
- 13.3. Stallergenes Greer
- 13.4. HAL Allergy Group
- 13.5. DBV Technologies
- 13.6. Merck KGaA
- 13.7. Aimmune Therapeutics
- 13.8. Carcassia
- 13.9. Anergis
- 13.10. Biomay AG
- 13.11. Other Notable Players
List of Tables
- TABLE 1 Global Allergy Immunotherapy Market By Allergy, 2023-2033, USD (Million)
- TABLE 2 Global Allergy Immunotherapy Market By Treatment, 2023-2033, USD (Million)
- TABLE 3 Global Allergy Immunotherapy Market By Distribution Channel, 2023-2033, USD (Million)
- TABLE 4 North America Allergy Immunotherapy Market By Allergy, 2023-2033, USD (Million)
- TABLE 5 North America Allergy Immunotherapy Market By Treatment, 2023-2033, USD (Million)
- TABLE 6 North America Allergy Immunotherapy Market By Distribution Channel, 2023-2033, USD (Million)
- TABLE 7 U.S. Allergy Immunotherapy Market By Allergy, 2023-2033, USD (Million)
- TABLE 8 U.S. Allergy Immunotherapy Market By Treatment, 2023-2033, USD (Million)
- TABLE 9 U.S. Allergy Immunotherapy Market By Distribution Channel, 2023-2033, USD (Million)
- TABLE 10 Canada Allergy Immunotherapy Market By Allergy, 2023-2033, USD (Million)
- TABLE 11 Canada Allergy Immunotherapy Market By Treatment, 2023-2033, USD (Million)
- TABLE 12 Canada Allergy Immunotherapy Market By Distribution Channel, 2023-2033, USD (Million)
- TABLE 13 Rest of North America Allergy Immunotherapy Market By Allergy, 2023-2033, USD (Million)
- TABLE 14 Rest of North America Allergy Immunotherapy Market By Treatment, 2023-2033, USD (Million)
- TABLE 15 Rest of North America Allergy Immunotherapy Market By Distribution Channel, 2023-2033, USD (Million)
- TABLE 16 UK and European Union Allergy Immunotherapy Market By Allergy, 2023-2033, USD (Million)
- TABLE 17 UK and European Union Allergy Immunotherapy Market By Treatment, 2023-2033, USD (Million)
- TABLE 18 UK and European Union Allergy Immunotherapy Market By Distribution Channel, 2023-2033, USD (Million)
- TABLE 19 UK Allergy Immunotherapy Market By Allergy, 2023-2033, USD (Million)
- TABLE 20 UK Allergy Immunotherapy Market By Treatment, 2023-2033, USD (Million)
- TABLE 21 UK Allergy Immunotherapy Market By Distribution Channel, 2023-2033, USD (Million)
- TABLE 22 Germany Allergy Immunotherapy Market By Allergy, 2023-2033, USD (Million)
- TABLE 23 Germany Allergy Immunotherapy Market By Treatment, 2023-2033, USD (Million)
- TABLE 24 Germany Allergy Immunotherapy Market By Distribution Channel, 2023-2033, USD (Million)
- TABLE 25 Spain Allergy Immunotherapy Market By Allergy, 2023-2033, USD (Million)
- TABLE 26 Spain Allergy Immunotherapy Market By Treatment, 2023-2033, USD (Million)
- TABLE 27 Spain Allergy Immunotherapy Market By Distribution Channel, 2023-2033, USD (Million)
- TABLE 28 Italy Allergy Immunotherapy Market By Allergy, 2023-2033, USD (Million)
- TABLE 29 Italy Allergy Immunotherapy Market By Treatment, 2023-2033, USD (Million)
- TABLE 30 Italy Allergy Immunotherapy Market By Distribution Channel, 2023-2033, USD (Million)
- TABLE 31 France Allergy Immunotherapy Market By Allergy, 2023-2033, USD (Million)
- TABLE 32 France Allergy Immunotherapy Market By Treatment, 2023-2033, USD (Million)
- TABLE 33 France Allergy Immunotherapy Market By Distribution Channel, 2023-2033, USD (Million)
- TABLE 34 Rest of Europe Allergy Immunotherapy Market By Allergy, 2023-2033, USD (Million)
- TABLE 35 Rest of Europe Allergy Immunotherapy Market By Treatment, 2023-2033, USD (Million)
- TABLE 36 Rest of Europe Allergy Immunotherapy Market By Distribution Channel, 2023-2033, USD (Million)
- TABLE 37 Asia Allergy Immunotherapy Market By Allergy, 2023-2033, USD (Million)
- TABLE 38 Asia Allergy Immunotherapy Market By Treatment, 2023-2033, USD (Million)
- TABLE 39 Asia Allergy Immunotherapy Market By Distribution Channel, 2023-2033, USD (Million)
- TABLE 40 China Allergy Immunotherapy Market By Allergy, 2023-2033, USD (Million)
- TABLE 41 China Allergy Immunotherapy Market By Treatment, 2023-2033, USD (Million)
- TABLE 42 China Allergy Immunotherapy Market By Distribution Channel, 2023-2033, USD (Million)
- TABLE 43 Japan Allergy Immunotherapy Market By Allergy, 2023-2033, USD (Million)
- TABLE 44 Japan Allergy Immunotherapy Market By Treatment, 2023-2033, USD (Million)
- TABLE 45 Japan Allergy Immunotherapy Market By Distribution Channel, 2023-2033, USD (Million)
- TABLE 46 India Allergy Immunotherapy Market By Allergy, 2023-2033, USD (Million)
- TABLE 47 India Allergy Immunotherapy Market By Treatment, 2023-2033, USD (Million)
- TABLE 48 India Allergy Immunotherapy Market By Distribution Channel, 2023-2033, USD (Million)
- TABLE 49 Australia Allergy Immunotherapy Market By Allergy, 2023-2033, USD (Million)
- TABLE 50 Australia Allergy Immunotherapy Market By Treatment, 2023-2033, USD (Million)
- TABLE 51 Australia Allergy Immunotherapy Market By Distribution Channel, 2023-2033, USD (Million)
- TABLE 52 South Korea Allergy Immunotherapy Market By Allergy, 2023-2033, USD (Million)
- TABLE 53 South Korea Allergy Immunotherapy Market By Treatment, 2023-2033, USD (Million)
- TABLE 54 South Korea Allergy Immunotherapy Market By Distribution Channel, 2023-2033, USD (Million)
- TABLE 55 Latin America Allergy Immunotherapy Market By Allergy, 2023-2033, USD (Million)
- TABLE 56 Latin America Allergy Immunotherapy Market By Treatment, 2023-2033, USD (Million)
- TABLE 57 Latin America Allergy Immunotherapy Market By Distribution Channel, 2023-2033, USD (Million)
- TABLE 58 Brazil Allergy Immunotherapy Market By Allergy, 2023-2033, USD (Million)
- TABLE 59 Brazil Allergy Immunotherapy Market By Treatment, 2023-2033, USD (Million)
- TABLE 60 Brazil Allergy Immunotherapy Market By Distribution Channel, 2023-2033, USD (Million)
- TABLE 61 Mexico Allergy Immunotherapy Market By Allergy, 2023-2033, USD (Million)
- TABLE 62 Mexico Allergy Immunotherapy Market By Treatment, 2023-2033, USD (Million)
- TABLE 63 Mexico Allergy Immunotherapy Market By Distribution Channel, 2023-2033, USD (Million)
- TABLE 64 Rest of Latin America Allergy Immunotherapy Market By Allergy, 2023-2033, USD (Million)
- TABLE 65 Rest of Latin America Allergy Immunotherapy Market By Treatment, 2023-2033, USD (Million)
- TABLE 66 Rest of Latin America Allergy Immunotherapy Market By Distribution Channel, 2023-2033, USD (Million)
- TABLE 67 Middle East and Africa Allergy Immunotherapy Market By Allergy, 2023-2033, USD (Million)
- TABLE 68 Middle East and Africa Allergy Immunotherapy Market By Treatment, 2023-2033, USD (Million)
- TABLE 69 Middle East and Africa Allergy Immunotherapy Market By Distribution Channel, 2023-2033, USD (Million)
- TABLE 70 GCC Allergy Immunotherapy Market By Allergy, 2023-2033, USD (Million)
- TABLE 71 GCC Allergy Immunotherapy Market By Treatment, 2023-2033, USD (Million)
- TABLE 72 GCC Allergy Immunotherapy Market By Distribution Channel, 2023-2033, USD (Million)
- TABLE 73 Africa Allergy Immunotherapy Market By Allergy, 2023-2033, USD (Million)
- TABLE 74 Africa Allergy Immunotherapy Market By Treatment, 2023-2033, USD (Million)
- TABLE 75 Africa Allergy Immunotherapy Market By Distribution Channel, 2023-2033, USD (Million)
- TABLE 76 Rest of Middle East and Africa Allergy Immunotherapy Market By Allergy, 2023-2033, USD (Million)
- TABLE 77 Rest of Middle East and Africa Allergy Immunotherapy Market By Treatment, 2023-2033, USD (Million)
- TABLE 78 Rest of Middle East and Africa Allergy Immunotherapy Market By Distribution Channel, 2023-2033, USD (Million)
List of Figures
- FIG. 1 Global Allergy Immunotherapy Market: Market Coverage
- FIG. 2 Research Methodology and Data Sources
- FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
- FIG. 4 Global Allergy Immunotherapy Market: Quality Assurance
- FIG. 5 Global Allergy Immunotherapy Market, By Allergy, 2024
- FIG. 6 Global Allergy Immunotherapy Market, By Treatment, 2024
- FIG. 7 Global Allergy Immunotherapy Market, By Distribution Channel, 2024
- FIG. 8 Global Allergy Immunotherapy Market, By Geography, 2024
- FIG. 9 Market Geographical Opportunity Matrix - Global Allergy Immunotherapy Market, 2024
- FIG. 10 Market Positioning of Key Allergy Immunotherapy Market Players, 2024
- FIG. 11 Global Allergy Immunotherapy Market, By Allergy, 2024 Vs 2033, %
- FIG. 12 Global Allergy Immunotherapy Market, By Treatment, 2024 Vs 2033, %
- FIG. 13 Global Allergy Immunotherapy Market, By Distribution Channel, 2024 Vs 2033, %
- FIG. 14 U.S. Allergy Immunotherapy Market (US$ Million), 2023 - 2033
- FIG. 15 Canada Allergy Immunotherapy Market (US$ Million), 2023 - 2033
- FIG. 16 Rest of North America Allergy Immunotherapy Market (US$ Million), 2023 - 2033
- FIG. 17 UK Allergy Immunotherapy Market (US$ Million), 2023 - 2033
- FIG. 18 Germany Allergy Immunotherapy Market (US$ Million), 2023 - 2033
- FIG. 19 Spain Allergy Immunotherapy Market (US$ Million), 2023 - 2033
- FIG. 20 Italy Allergy Immunotherapy Market (US$ Million), 2023 - 2033
- FIG. 21 France Allergy Immunotherapy Market (US$ Million), 2023 - 2033
- FIG. 22 Rest of Europe Allergy Immunotherapy Market (US$ Million), 2023 - 2033
- FIG. 23 China Allergy Immunotherapy Market (US$ Million), 2023 - 2033
- FIG. 24 Japan Allergy Immunotherapy Market (US$ Million), 2023 - 2033
- FIG. 25 India Allergy Immunotherapy Market (US$ Million), 2023 - 2033
- FIG. 26 Australia Allergy Immunotherapy Market (US$ Million), 2023 - 2033
- FIG. 27 South Korea Allergy Immunotherapy Market (US$ Million), 2023 - 2033
- FIG. 28 Rest of Asia Allergy Immunotherapy Market (US$ Million), 2023 - 2033
- FIG. 29 Brazil Allergy Immunotherapy Market (US$ Million), 2023 - 2033
- FIG. 30 Mexico Allergy Immunotherapy Market (US$ Million), 2023 - 2033
- FIG. 31 Rest of Latin America Allergy Immunotherapy Market (US$ Million), 2023 - 2033
- FIG. 32 GCC Allergy Immunotherapy Market (US$ Million), 2023 - 2033
- FIG. 33 Africa Allergy Immunotherapy Market (US$ Million), 2023 - 2033
- FIG. 34 Rest of Middle East and Africa Allergy Immunotherapy Market (US$ Million), 2023 - 2033
